1-(3-{3-[5-(2,3-dihydrobenzo[1,4]dioxin-6-ylamino)-[1,3,4]oxadiazol-2-yl]pyridin-2-ylamino}propyl)pyrrolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 1-(3-{3-[5-(2,3-dihydrobenzo[1,4]dioxin-6-ylamino)-[1,3,4]oxadiazol-2-yl]pyridin-2-ylamino}propyl)pyrrolidin-2-one
• 英文别名: 1-[3-[[3-[5-(2,3-Dihydro-1,4-benzodioxin-6-ylamino)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]amino]propyl]pyrrolidin-2-one
• 化学式: C₂₂H₂₄N₆O₄
• 分子量: 436.47
• InChiKey: BKHAUNURCOYSRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-氯烟酸乙酯 在 一水合肼 、 三乙胺 、 2,3-二脱氧胞啶 作用下， 以 二氯甲烷 、 二甲基亚砜 、 异丙醇 、 甲苯 为溶剂， 生成 1-(3-{3-[5-(2,3-dihydrobenzo[1,4]dioxin-6-ylamino)-[1,3,4]oxadiazol-2-yl]pyridin-2-ylamino}propyl)pyrrolidin-2-one
  参考文献：
  名称：

  Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines

  摘要：

  Oxadiazole derivatives were synthesized and evaluated for their ability to inhibit tubulin polymerization and to cause mitotic arrest in tumor cells. The most potent compounds inhibited tubulin polymerization at concentrations below 1 mu M. Lead analogs caused mitotic arrest of A431 human epidermoid cells and cells derived from multi-drug resistant tumors (10, EC50 = 7.8 nM). Competition for the colchicine binding site and pharmacokinetic properties of selected potent compounds were also investigated and are reported herein, along with structure-activity relationships for this novel series of antimitotic agents. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.094

文献信息

• Heterocyclic compounds and their use as anticancer agents
  申请人：Chen Xiaoling

  公开号：US20090318438A1

  公开（公告）日：2009-12-24

  The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture.

  本发明涉及具有抗癌活性的杂环化合物，以及包含这些化合物的制药组合物，使用这些化合物和组合物治疗哺乳动物的疾病和病症的方法以及它们的制造方法。
• HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS
  申请人：Chen Xiaoling

  公开号：US20090048301A1

  公开（公告）日：2009-02-19

  The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture.

  本发明涉及具有抗癌活性的杂环化合物、含有这种化合物的制药组合物、使用这种化合物和组合物治疗哺乳动物疾病和病症的方法以及它们的制造方法。
• [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS<br/>[FR] COMPOSES HETEROCYCLIQUES ET LEUR UTILISATION COMME AGENTS ANTICANCEREUX
  申请人：IMCLONE SYSTEMS INC

  公开号：WO2005004818A2

  公开（公告）日：2005-01-20

  [EN] The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture.
  [FR] L'invention concerne des composés hétérocycliques à activité anticancéreuse, ainsi que des compositions pharmaceutiques contenant de tels composés, ainsi que des méthodes pour traiter des affections et des états chez des mammifères, à l'aide desdits composés et desdites compositions et des procédés de préparation correspondants.
• Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines
  作者：Xiaohu Ouyang、Evgueni L. Piatnitski、Vatee Pattaropong、Xiaoling Chen、Hai-Ying He、Alexander S. Kiselyov、Avdhoot Velankar、Joel Kawakami、Marc Labelle、Leon Smith、Julia Lohman、Sui Ping Lee、Asra Malikzay、James Fleming、Jason Gerlak、Ying Wang、Robin L. Rosler、Kai Zhou、Stan Mitelman、Margarita Camara、David Surguladze、Jacqueline F. Doody、M. Carolina Tuma

  DOI：10.1016/j.bmcl.2005.11.094

  日期：2006.3

  Oxadiazole derivatives were synthesized and evaluated for their ability to inhibit tubulin polymerization and to cause mitotic arrest in tumor cells. The most potent compounds inhibited tubulin polymerization at concentrations below 1 mu M. Lead analogs caused mitotic arrest of A431 human epidermoid cells and cells derived from multi-drug resistant tumors (10, EC50 = 7.8 nM). Competition for the colchicine binding site and pharmacokinetic properties of selected potent compounds were also investigated and are reported herein, along with structure-activity relationships for this novel series of antimitotic agents. (C) 2005 Elsevier Ltd. All rights reserved.